ArticleOcular immunology and inflammation2017
Adalimumab for Ocular Inflammation.
Article in Ocular immunology and inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in medicine · 2019Pooled it
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review.Medicine · 2017Pooled it
- Single-cell and spatial transcriptomic analyses of gene therapy-associated retinal inflammation in non-human primates.Molecular therapy. Advances · 2026Article
- Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective.Journal of comparative effectiveness research · 2025Article
- The sequential therapy for non-infectious scleritis: A case report.SAGE open medical case reports · 2025Article
- Article
- Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.Eye (London, England) · 2024Article
- Surgical induced necrotizing scleritis following intraocular lens replacement.Journal of ophthalmic inflammation and infection · 2023Article
- Inhibitory effect of fucoidan on TNF-α-induced inflammation in human retinal pigment epithelium cells.Frontiers in nutrition · 2023Article
- Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis.Journal of clinical medicine · 2022Article
- Sarcoid Uveitis: An Intriguing Challenger.Medicina (Kaunas, Lithuania) · 2022Review
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.Ophthalmology and therapy · 2021Review
- Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives.Journal of clinical medicine · 2021Review
- Adalimumab in patients with vision-threatening uveitis: real-world clinical experience.BMJ open ophthalmology · 2021Article
- Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study.Journal of clinical medicine · 2020Article
- Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.Inflammopharmacology · 2020Article
- Noninfectious Autoimmune Scleritis: Recognition, Systemic Associations, and Therapy.Current rheumatology reports · 2020Review
- [Pharmacological treatment strategies and surgical options for uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
- Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study.Mediators of inflammation · 2019Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
purposeTo evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases.
methodsCharacteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity.
resultsIn total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months.
conclusionsAdalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.